
Opinion|Videos|May 17, 2024
KEYNOTE-564: Adjuvant Pembrolizumab in Renal Cell Carcinoma
Dr Pal discusses the study design and results of the KEYNOTE-564 trial, and Benjamin Gerendash, MSN, RN, AGACNP-BC, discusses the management of adverse events associated with pembrolizumab.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
2
Exploring Psilocybin-Assisted Therapy for Cancer Patients' Trauma
3
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
4
Allostatic Load: The Role of Chronic Stress in Predicting Early-Onset Cancer Risk
5





























